YAP1 and cancer: Interestingly, we found that the high expression levels of EGFR, TEAD, and YAP1 were associated with resistance of cancer cell lines to several clinical anticancer drugs (navitoclax, alisertib, belinistat, tivantinib, niclosamide, necrostatin-1, alvocidib, etc.)and NSC drugs (NSC19630, NSC632839, NSC23766, NSC48300, and NSC95397).